KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Cash from Financing Activities (2017 - 2025)

Historic Cash from Financing Activities for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $59.4 million.

  • Amneal Pharmaceuticals' Cash from Financing Activities rose 16436.99% to $59.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$82.6 million, marking a year-over-year increase of 6714.09%. This contributed to the annual value of -$211.8 million for FY2024, which is 36.79% up from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' Cash from Financing Activities is $59.4 million, which was up 16436.99% from -$41.7 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Cash from Financing Activities ranged from a high of $59.4 million in Q3 2025 and a low of -$100.8 million during Q4 2023
  • Its 5-year average for Cash from Financing Activities is -$36.3 million, with a median of -$38.1 million in 2021.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first crashed by 35487.44% in 2023, then surged by 16436.99% in 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$30.4 million in 2021, then grew by 26.96% to -$22.2 million in 2022, then crashed by 354.87% to -$100.8 million in 2023, then skyrocketed by 39.3% to -$61.2 million in 2024, then skyrocketed by 197.12% to $59.4 million in 2025.
  • Its Cash from Financing Activities was $59.4 million in Q3 2025, compared to -$41.7 million in Q2 2025 and -$39.2 million in Q1 2025.